Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Cited by (629)

Items 501–600 of 629

1. Preparing for COVID-19 Vaccination: Guidelines for Healthcare Personnel
   Young Rong Kim, Dae Jung Kim, Young Hwa Choi · 2021 · Korean Journal of Healthcare-Associated Infection Control and Prevention
2. Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review
   Guanran Zhang, Sirui Kuang, Xiaoli Zhang · 2022 · Human Vaccines & Immunotherapeutics
3. SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice
   Ekaterina A. Volosnikova, Iuliia A. Merkuleva, Tatiana I. Esina, Д. Н. Щербаков, Mariya Borisovna Borgoyakova, А. А. Исаева, Valentina S. Nesmeyanova, Н. В. Волкова, S. V. Belenkaya, Anna V. Zaykovskaya et al. · 2023 · Vaccines
4. Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs
   Juan Mosqueda, Diego Josimar Hernández-Silva, Marco Antonio Vega‐López, Lineth Juliana Vega-Rojas, Rolando Beltrán, Andrés Velasco-Elizondo, María del Carmen Ramírez‐Estudillo, Mario Fragoso-Saavedra, Chyntia Pérez-Almeida, Jesús Hernández et al. · 2023 · Frontiers in Immunology
5. Mitigation strategies to safely conduct HIV treatment research in the context of COVID‐19
   Merle Henderson, Sarah J. Fidler, Beatriz Mothe, Beatriz Gilda Jegerhorn Grinsztejn, Bridget Gabrielle Haire, Simon Collins, Jillian S. Y. Lau, Maureen Luba, Ian Sanne, Roger Tatoud et al. · 2022 · Journal of the International AIDS Society
6. Emergence of the SARS-CoV-2 Omicron Variant: Current Treatments and Vaccines for COVID-19
   Valerie Vidian, Dikson, Vivian Litanto, Suawa Natania Abigail Christy, Juandy Jo · 2022 · Exploratory Research and Hypothesis in Medicine
7. Efektivitas Vaksin Covid-19 dalam Kinerjanya untuk Memodulasi Imunitas Tubuh Melawan Infeksi SARS-COV-2
   Andika Ridwan Nugraha Harahap · 2022 · Indonesian Journal of Nursing and Health Sciences
8. Beyond Spike: Identification of nine highly prevalent SARS-CoV-2-specific CD8 T-cell epitopes in a large Norwegian cohort
   Saskia Meyer, Isaac Blaas, Ravi Chand Bollineni, Marina Delić-Šarac, Trung The Tran, Cathrine F. Knetter, Ke‐Zheng Dai, Torfinn Støve Madssen, John Torgils Vaage, Alice Gustavsen et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
9. Bioinformatic analysis of B and T cell epitopes from SARS-CoV-2 Spike, Membrane and Nucleocapsid proteins as a strategy to assess possible cross-reactivity between emerging variants, including Omicron, and other human coronaviruses
   Diana Laura Pacheco-Olvera, Stephanie Saint Remy-Hernández, María Guadalupe García-Valeriano, Tania Rivera-Hernández, Constantino III Roberto López-Macías · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
10. Comparative Effectiveness of BNT162b2 and NVX-CoV2373 Vaccines in Korean Adults
    Seon Kyeong Park, Young June Choe, Seung‐Ah Choe, Benjamin John Cowling, Ji Hae Hwang, Ju Hee Lee, Kil Hun Lee, Seonju Yi, Sangwon Lee, Geun‐Yong Kwon et al. · 2023 · medRxiv
11. Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19
    Isadora Sousa de Oliveira, Isabela Gobbo Ferreira, Beatriz de Cássia da Silva Jacob, Kiara Cristhina Torres Cardenas, Felipe A. Cerni, Djane Clarys Baía-da-Silva, Eliane Candiani Arantes, Wuelton Marcelo Monteiro, Manuela B. Pucca · 2023 · Toxins
12. Methodical and Immunological Insights of Prime COVID-19 Vaccines
    Wilson Pearl Evangeline, Sakthivelnathan Divyasri, Chandrasekaran Akshaya, Sekar Sruthi, Selvaraj Barathi, Rangasamy Kirubakaran, Kandasamy Nagarajan ArulJothi · 2023 · Coronaviruses
13. Frequency of SARS-CoV-2 variants identified by real-time PCR in the AUNA healthcare network, Peru
    Tamin Ortiz-Gómez, Andrea C. Gómez, Brigitte Chuima, Alejandra Zevallos, Karen Ocampo, Diana Torres, Joseph A. Pinto · 2024 · Frontiers in Public Health
14. Impact of Immunosuppressants and Vaccination on COVID-19 Outcomes in Autoimmune Patients and Solid Organ Transplant Recipients: A Nationwide Propensity Score-Matched Study
    MinDong Sung, Young Sam Kim, Chan Yeong Cho, Yongeun Son, Dong Wook Kim, Su Hwan Lee · 2024 · Vaccines
15. Emerging Biopharmaceutical Technologies and Trends
    David W. Wood, Izabela Gierach · 2024 · Springer eBooks
16. Accelerated vaccine process development by orthogonal protein characterization
    D. Andrew James, Lisa Szymkowicz, Lois Yin, Hetvi Shah, Michael Leach, Roman M. Chicz · 2025 · Scientific Reports
17. A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations
    Soo Aleman, Gustaf Ahlén, Jingyi Yan, Per T Ljungman, Peter Bergman, C. An Binh Nordentoft, Sofia Appelberg, Arlisa Alisjahbana, Matteo Cadossi, Simona Salati et al. · 2026 · Molecular Therapy Advances
18. Virus‐Like Nanoparticles for Vaccine Development and Drug Delivery
    Defeng Li, Meifeng Yang, Ning-ning Yue, Longbin Huang, Chen Kong, Yuan Zhang, Cheng‐mei Tian, Zhao Hai-lan, Qian‐jun Luo, Hua‐lin Ma et al. · 2026 · Reviews in Medical Virology
19. Advances in the delivery of COVID-19 vaccines
    Kevin B. Ita · 2022 · American Journal of Biopharmacy and Pharmaceutical Sciences
20. New Insights on Cardiomyopathy [Working Title]
    Sameh M. Said · 2022 · IntechOpen eBooks
21. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
    Muneerah Smith, Gaurav Kwatra, Alane Izu, Andrew J. M. Nel, Clare Cutland, Khatja Ahmed, Vicky Lynne Baillie, Shaun Lawrence Barnabas, Qasim Ebrahim Bhorat, Carmen Briner et al. · 2023 · Viruses
22. The impact of influenza vaccination on surgical outcomes in COVID-19 positive patients: An analysis of 43,580 patients
    Susan M. Taghioff, Benjamin R. Slavin, Shefali Mehra, Tripp Holton, Devinder Pal Singh · 2023 · PLoS ONE
23. Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials
    Sergey V. Goryaynov, Olesya Y. Gurova · 2024 · Vaccines
24. COVID-19 vaccine confidence index and economic uncertainty indices: empirical evidence from the payment-based system cryptocurrency market
    S. Havidz, E. V. Anastasia, N. Patricia, P. Diana · 2024 · International Journal of Social Economics
25. Efficacy of adjuvant-associated COVID-19 vaccines against SARS-CoV-2 variants of concern in randomized controlled trials: A systematic review and meta-analysis
    Meng-qun Cheng, Zhiying Weng, Rong Li, Song Gao · 2024 · Medicine
26. COVID 19: Prevention and treatment through the Indian perspective
    Harish Chandra, Archana Yadav, Rajendra Prasad, Kalpana Sagar, Nitin Bhardwaj, Kartikey Kumar Gupta, Ghanshyam Singh Thakur, Manisha Nigam, Raffaele Pezzani, João Paulo Martins de Lima et al. · 2024 · Cytokine
27. Diphyllin elicits a doubled-pronged attack on the entry of SARS-CoV-2 by inhibiting cathepsin L and furin
    Binli Mao, V. Le-Trilling, Haihuan Tang, Jie Hu, Mona S. Schmitz, Kimberly Barbet, Dan Xu, Zhen Wei, Beinu Guo, Denise Mennerich et al. · 2024 · Virus Research
28. Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial
    Renan James Lim, Xiangyan Qiu, Robert Neil F. Leong, Jose Limuel Gutierrez, Ahmad Halima, Mohamed H. Mostafa, Yasser Ghoneim, Mostafa Abdrabo, Moaz Rashad, Suad Hannawi et al. · 2024 · Clinical and Experimental Vaccine Research
29. Distinct immune responses in people living with HIV following SARS-CoV-2 recovery
    Dieter Mielke, Shuying Sue Li, Daniel J. Schuster, Xiaohong Li, Jiani Hu, Shelly Karuna, Kelly E. Seaton, Caroline Brackett, Brooke Dunn, Taylor Keyes et al. · 2025 · Communications Medicine
30. Coronavirus variant threatens global recovery
    Elie Dolgin · 2021 · Nature Africa
31. Estrategia de vacunación en México y diversidad de vacunas.
    Alejandra Noriega-Rubalcaba, Eduardo Nieto-Ortega, Emiliano Vivanco-Gómez, Alejandro Durán-Méndez, Daniela P. Ortega, Alberto N. Peón · 2021
32. The future of tumor vaccines in the post‐COVID‐19 era—Current challenges
    PANAGIOTIS F. CHRISTOPOULOS · 2021 · Immunity Inflammation and Disease
33. The effect of RNA and non-RNA vaccines in variants of Covid-19: A narrative review
    Maryam Rahmannia, Shahryar Rajai Firouz Abadi, Ahad Hasan Syed Hasani, F. Khanali, Fatemeh Vosoughian, Roya Mirzaei, H. Esmaeili · 2021 · Pakistan Journal of Medical & Health Sciences
34. A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era
    Sean C. Taylor · 2021 · Journal of Clinical Virology Plus
35. Safety and efficacy of the Novavax vaccine—a narrative review
    Sanny Zi Lung Choo, Shyh Poh Teo · 2021 · Aging Pathobiology and Therapeutics
36. New drug: SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
    2022 · Australian Prescriber
37. Comparison of COVID-19 Vaccines Introduced in Korea
    Chang-Gun Lee, Dongsup Lee · 2022 · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters
38. COVID-19 Vaccine Clinical Trials: A Bird’s Eye Perspective
    Pujitha Vallivedu Chennakesavulu, Gaurav Venkat Cuddapah, Mayura Reddy Keesara, Jyothik Varun Inampudi, Amulya Arremsetty, Sushma Moka, Swamy Miryala · 2022 · Cureus
39. Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India
    Deep Inder, Seema Manak, Md. Faiz Akram, Pawan Kumar · 2022 · Saudi Journal for Health Sciences
40. Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2
    Jasdeep Singh, Nasreen Z. Ehtesham, Subhash Hira, Umid Kumar Shrestha, Seyed E. Hasnain · 2022 · Springer eBooks
41. Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections
    Arbind Kumar, Aashish Sharma, Narendra Vijay Tirpude, Yogendra Shantaram Padwad, Shaifali Sharma, Sanjay Kumar · 2022 · Infectious diseases
42. Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome – Definition, Clinical Scenarios, Diagnosis, and Management
    Claudio Stefano Centorbi, Enrica Garau, Leonardo Borsi, Valerio Brambilla, Lorenzo Brambilla, Davide Lazzeroni · 2023 · IntechOpen eBooks
43. Speckle tracking echocardiographic assessment of Left ventricular global longitudinal strain in patients recovered from COVID-19
    Abdelrahman Abdelrahman, Heba Abd El-Kader Mansour, Mohamed Ahmed Hamouda, Safaa Imam · 2023 · Benha Medical Journal
44. Lecciones aprendidas del COVID-19: Una mirada interdisciplinaria
    2023
45. Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost
    Daniel J. Sheward, Marco Mandolesi, Egon Urgard, Changil Kim, Leo Hanke, Laura Perez Vidakovics, Alec P. Pankow, Natalie L. Smith, Xaquín Castro Dopico, Gerald M. McInerney et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
46. Isolation and characterization of SARS-CoV-2 VOC, 20H/501Y.V2, from UAE travelers
    Pragya Dhruv Yadav, Prasad Sarkale, Alpana Razdan, Nivedita Gupta, Dimpal A. Nyayanit, Rima Rakeshkumar Sahay, Varsha Atul Potdar, Deepak Y. Patil, Shreekant Baradkar, Abhinendra Kumar et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
47. Applying Philosophy, Logic, and Rational Argumentation to the Severe Acute Respiratory Syndrome Coronavirus-2 Pandemic Response
    Ari R. Joffe, David Redman · 2021 · Preprints.org
48. Models and Mechanisms for COVID-19 Research
    Kirsty M. Hooper, E. Elizabeth Patton · 2021 · Disease Models & Mechanisms
49. Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2
    Fatima Amanat, Shirin Strohmeier, Philip S. Meade, Nicholas Dambrauskas, Barbara Mühlemann, Derek J. Smith, Vladimir I. Vigdorovich, D. Noah Sather, Lynda Coughlan, Florian Krammer · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
50. Algorithm for the Quantitation of Variants of Concern for Rationally Designed Vaccines Based on the Isolation of SARS-CoV-2 Hawaiʻi Lineage B.1.243
    David P. Maison, Lauren Lei Ching, Sean B. Cleveland, Alanna C. Tseng, Eileen T. Nakano, Cecilia M. Shikuma, Vivek R. Nerurkar · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
51. New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019
    Chao Zhang, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2022 · Journal of Thoracic Oncology
52. NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4 + and CD8 + T cell responses
    Carolyn Rydyznski Moderbacher, Christina Kim, José Mateus, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Daniela Weiskopf, Alessandro Sette, Louis F Fries, Gregory Glenn et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
53. Programming the lymph node immune response with Amphiphile-CpG induces potent cellular and humoral immunity following COVID-19 subunit vaccination in mice and non-human primates
    Lochana M. Seenappa, Aniela Jakubowski, Martin Peter Steinbuck, Erica Palmer, Christopher M. Haqq, Crystal Carter, Jane A. Fontenot, Francois J. Villinger, Lisa Kristin McNeil, Peter C. DeMuth · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
54. Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis
    Bingyi Yang, Xiaotong Huang, Huizhi Gao, Nancy Leung, Tim K. Tsang, Benjamin John Cowling · 2022 · Research Square
55. A randomized, controlled study to evaluate the safety and immunogenicity of a heterologous booster dose of an adjuvanted SARS CoV-2 recombinant spike protein vaccine in adults
    Prasad Suryakant Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Kewalchand Lalwani, Srikanth Prasad Tripathy, Sonali Kar, Sidram K. Raut, Praveen Kulkarni, Aditi A. Apte, Ashish Bavdekar et al. · 2023 · Research Square
56. Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
    Germán Áñez, Karen L. Kotloff, Cynthia L. Gay, Joy Nelson, Haoua Dunbar, Shane Cloney-Clark, Alice McGarry, Wayne Woo, Iksung Cho, Joyce S. Plested et al. · 2023 · medRxiv
57. Une variante du coronavirus menace la sortie de crise à l’échelle mondiale
    Elie Dolgin · 2021 · Nature Africa
58. COVID-19 Rapid Guideline - Organisation and Management in Low Resource Countries
    Rama Vancheeswaran, Andy Barlow, Phyoe Kyaw Pyae, A O'Neill, V Vancheeswaran, H Mitchell, Rigers Cama, M Van der Watt · 2021 · The Physician
59. COVID-19 Vaccines: Fabrication Techniques and Current Status
    Lakhvir Kaur, Ayushi Mahajan, Gurjeet Singh, Ravi Kumar Dhawan, Lovepreet Singh, Anureet Kaur · 2021 · Coronaviruses
60. Third-Party Materials
    Ryan Benjamin Abbott · 2020 · Cambridge University Press eBooks
61. Protein-based RBD-C-tag COVID-19 Vaccination Candidate Elicits Protection Activity against SARS-COV-2 Variant Infection
    Jaganathan Subramani, Namir Shaabani, Dhwani Shetty, Haiwa Wu, Sunkuk Kwon, Wenzhao Li, Chanyu Yue, Christoph Lahtz, Adela Ramirez-Torres, Heyue Zhou et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
62. Desarrollo de las Vacunas contra el SARS-CoV-2 y las implicancias relacionadas a la aparición de las variantes del virus
    Claudio Franco Lanata, Lucie Ecker, Rubelio Cornejo, Carlos R. Celis, Carmen del Pilar Díaz-Parra, Sheby Annie Ricalde Ponce de León, Omar Flores, Mayra Ochoa, Bia Peña, Ana I. Gil · 2021 · Diagnóstico
63. Characterization of Specific Humoral Immunity in Asymptomatic SARS-CoV-2 Infection
    Yingying Deng, Jiaxin Zheng, Yong Lin, Ailong Huang · 2021 · Infectious Diseases & Immunity
64. Comparing Immune Responses to Inactivated Vaccines Against SARS-CoV-2 Between People Living With HIV and HIV-Negative Individuals: A Cross-Sectional Study in China
    Xiaojie Huang, Ying Yan, Bin Su, Dong Xiao, Maohe Yu, Xia Jin, Junyi Duan, Xiangjun Zhang, Shimin Zheng, Yuan Fang et al. · 2021 · Viruses
65. Dosis de refuerzo con la vacuna BNT162b2 en población que recibió el esquema de vacunación completa para COVID-19 en Perú: Un análisis crítico de la evidencia actual*
    Carlos Jesus Toro-Huamanchumo, José Alfredo Zavala-Loayza, Raisa N. Martinez‐Rivera, Verónica Peralta, Eric Ricardo Peña-Sánchez · 2021 · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
66. Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine
    Abhay Pratap Singh, Sachin Kumar · 2021 · Human Vaccines & Immunotherapeutics
67. Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
    Adrian Rice, Mohit Verma, Emily A. Voigt, Peter Battisti, Samuel Beaver, Sierra Reed, Kyle Dinkins, Shivani Mody, Lise Zakin, Shiho Tanaka et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
68. [Anthralin erythema: effect of concentration, contact time, oxidation products and corticosteroids. Clinical, reflection photometry and electron microscopy studies].
    M Puschmann · 1983 · PubMed
69. Novel universal SARS-CoV DNA vaccine inducing neutralizing antibodies to huCoV-19/WH01, Beta, Delta and Omicron variants and T cells to Bat-CoV
    K. S. Appelberg, G. Ahlén, Negin Nikoyan, Jing-Yi Yan, S. Weber, O. Larsson, U. Höglund, Soo Aleman, F. Weber, Emma Perlhamre et al. · 2022 · Research Square
70. PAKISTAN’S PERSPECTIVE ON COVID-19 VACCINES
    Taimoor Hassan, Saleha Saleha · 2021 · Gomal journal of Medical Sciences
71. A systematic review of the variants of Sars-Cov-2
    Mohammed Farhan Qureshi, Shoeb Qureshi · 2022 · International Journal of Science and Research Archive
72. SARS-CoV-2-Impfung: Auch bei "besonderen" Patienten
    Ulrich Seybold · 2022 · MMW - Fortschritte der Medizin
73. Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS Study
    José Alcamı́, Javier García‐Pérez, María González-Pérez, María Castillo de la Osa, Alberto Manuel Borobia, Luis Antonio Castaño, M.J. Bertran, Magda Campins, Antonio Portolés, David Lora et al. · 2022 · SSRN Electronic Journal
74. nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination
    Imran Shahid · 2022 · Dr Sulaiman Al Habib Medical Journal
75. SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
    Vincent Pavot, Catherine Berry, Michael Kishko, Natalie G. Anosova, Dean Huang, Tim Tibbitts, Alice Raillard, Sylviane Gautheron, Cindy Gutzeit, Marguerite Koutsoukos et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
76. Evidências científicas atualizadas sobre as vacinas para prevenção do SARS-COV-2 / Updated scientific evidence on vaccines for SARS-COV-2 prevention
    Evelyn de Kênya Lins Prates, Fernanda Amparo Ribeiro, Edmar Araújo de Lima Filho, Camila Damiani de Matos, Clara Bucater Veado, Welsher Braga Ribeiro Chaves, Velton Braga Ribeiro Chaves, Pedro Henrique Sulz Marx, Fernanda Ramos Rangel · 2022 · Brazilian Journal of Health Review
77. Legal Framework for the Design and Construction of COVID Hospitals in the Russian Federation
    Guzel Zufarovna Sitdikova, M. V. Lifanova, O. V. Kornelyuk · 2022 · Lecture notes in civil engineering
78. COVID-19 Vaccine Breakthrough Infections and Associated Factors in Kwekwe City, Zimbabwe, 2021
    Nyashadzashe Cosmas Makova, Mary Muchekeza, Addmore Chadambuka, Emmanuel Govha, Tsitsi Juru, Notion Tafara Gombe, Mufuta Tshimanga · 2022 · Open Journal of Epidemiology
79. Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
    Takeshi Arashiro, Tadaki Suzuki · 2021 · Uirusu
80. Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis
    Thi Ngoc Anh Hoang, Ha‐Linh Quach, Ngoc Van Hoang, Thien Van Tran, Phạm Quang Thái, FLORIAN M. VOGT · 2022 · SSRN Electronic Journal
81. BBIBP-CorV Vaccination Reduces COVID-19 Severity Rate and Accelerates Anti-Viral Antibody Responses in Heterologous Omicron Infection
    Yu-Jie Bao, Liheng He, Benjie Miao, Zhengrong Zhong, Guanzhu Lu, Yupan Bai, Qiming Liang, Yunchao Ling, Ping Ji, Bing Su et al. · 2022 · SSRN Electronic Journal
82. Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis
    Bingyi Yang, Xiaotong Huang, Huizhi Gao, Nancy Leung, Tim K. Tsang, Benjamin John Cowling · 2022 · Research Square
83. COVID-19 Vaccines Authorized by Stringent Regulatory Authorities and Vaccine Candidates Expecting Approval in 2021
    Melvin Sanicas, T. Anh Wartel, Merlin Sanicas · 2022 · Springer eBooks
84. Latest in COVID-19 Vaccine 'Candidates' Race
    Manar Fayiz Mousa Atoum, Dalia Abu Zreig, Laith Majed Abu Zreig · 2022 · Infectious Disorders - Drug Targets
85. Current Status of Vaccines Developed for SARS-CoV-2 Infection: A Review
    Carlos Andrés Marín Hoyos, Jean Paul Cappellaro Sánchez, Romel F Gómez, Monica Chavez Vivas · 2022 · Bangladesh Journal of Infectious Diseases
86. COVID-19 Vaccination in India
    Sadhan Kumar Ghosh, Anjan Adhikari, Anirudhha Mukhopadhyay, Samprikta Bose, Komal Sharma · 2022 · Springer eBooks
87. COVID-19 vaccines: Update of the vaccines in use and under development
    Rafaela Angotti Marta, Gisele Emy Kondo Nakamura, Bruno de Matos Aquino, Paulo Roberto Bignardi · 2022 · Vacunas (English Edition)
88. Literature analysis of the efficacy of COVID-19 vaccinations
    Tim Hulsen · 2022 · medRxiv
89. T Cell Immune Responses against SARS-CoV-2 in the With Corona Era
    Ji-Eun Oh · 2022 · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters
90. Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case–control study
    D. Bhattacharya, S. Kanungo, S. K. Palo, J. Kshatri, Matrujyoti Pattnaik, S. Ghosal, P. Mohapatra, Mo-Han C. Rao, Avinav Sahoo, Rudra Mishra et al. · 2023 · Frontiers in Public Health
91. Universal access to vaccines in post-COVID bioeconomy: Redesign for variants of concern and patent protection
    Cristina de Albuquerque Possas, Adelaide María de Souza Antunes, Alessandra Moreira de Oliveira, Suzanne de Oliveira Rodrigues Schumacher, Akira Homma · 2023 · Elsevier eBooks
92. Introductory Chapter: Global Research Efforts toward the Development of COVID-19 Vaccines
    Ibrokhim Yulchievich Abdurakhmonov · 2023 · IntechOpen eBooks
93. CRISPR Technology and Its Importance in SARS-CoV-2 Treatment
    Genç Saraçaydın, Özlem Özer Çakır · 2023 · Flora the Journal of Infectious Diseases and Clinical Microbiology
94. Vaccine Basics and the Development and Rollout of COVID-19 Vaccines
    Subramani Mani, Daniel O. Griffin · 2023 · Elsevier eBooks
95. Immunology of COVID-19
    Robert S. Wallis, Amit K. Srivastava, Andreas Wack, Charles A Knirsch · 2023 · Elsevier eBooks
96. Coronavirus Vaccines
    Stanley M. Perlman, Mark R. Denison · 2023 · Elsevier eBooks
97. Kronik Hastalığı Olan Bireylerin COVID-19 Aşısına Yönelik Tutumları ve Etkileyen Faktörlerin İncelenmesi
    Aysel SESCİ, Kadriye Sayın Kasar · 2023 · Ege Üniversitesi Hemşirelik Fakültesi Dergisi
98. Clinical characteristics, management, and prevention of coronavirus disease 2019
    Wei‐jie Guan, Jianxing He · 2023 · Frigid Zone Medicine
99. Carbohydrate‐Based Antiviral Vaccines
    Adrián Plata, Alberto Fernández‐Tejada · 2023
100. Comparison of the Prognosis and Mortality of Sars-Cov-2 Variants in Critically İll Patients
     Sinem Yalçın Bayrakçı · 2023 · Asian Journal of Research in Infectious Diseases